ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
|
Meeting Date
|
Thursday, November 7, 2024
|
|
Meetings
|
One-on-one and small group meetings: November 7, 2024
|
|
Management
Participants
|
Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO)
Joe Skelton, Chief Financial Officer (CFO)
Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)
Tyler Ehler, Senior Director, Investor Relations
|
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html
SOURCE I-Mab Biopharma
